All In Biotech

Drug Trial Radar · NCT07266116

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

A Phase Ib/II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQB2934 for Injection in Subjects With Systemic Light Chain Amyloidosis

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 26, 2025

Primary completion

Feb 2029

Study completion Nov 2029

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the safety and preliminary efficacy, pharmacokinetic (PK) characteristics, immunogenicity, and pharmacodynamic (PD) of TQB2934 for injection in subjects with systemic light chain amyloidosis, and to determine the recommended Phase II dose (RP2D). The Phase II plan involves enrolling 49 subjects, aiming to demonstrate that in adult subjects with relapsed/refractory systemic light chain amyloidosis who have previously received treatment with daratumumab and bortezomib, TQB2934 for injection significantly improves the hematological complete response (CR) rate compared to historical controls. The primary endpoint is the optimal hematological CR rate.

Conditions

  • Systemic Light Chain Amyloidosis

Interventions

  • TQB2934 injectionDrug

    TQB2934 for injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3). One end binds to the CD3 receptor on the surface of T cells, while the other end binds to BCMA, recruiting T cells to BCMA-positive cells. This can activate T cells, which then release granzyme, perforin, and other enzymes to kill BCMA-positive malignant plasma cells, thereby reducing the level of monoclonal immunoglobulin light chains in the body and delaying further organ damage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of subjects with adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs)Time frame: Baseline to the end of the study, about 4 years
  2. The best hematological response evaluated by the Independent Review Committee (IRC) is complete remission (CR)Time frame: Baseline to CR,about 1.5 years

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Southwest Hospital, Third Military Medical University (Army Medical University)

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangzhou First Municipal People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Peking University ShenZhen Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Not yet recruiting

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • Anyang People's Hospital

    Anyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • The second Affiliated hospital of dalian medical university

    Dalian, Liaoning, China · Not yet recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Qingdao municipal hosptial (group)

    Qingdao, Shandong, China · Not yet recruiting

  • Renji Hospital Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Chinese Academy of Medical Sciences Hematology Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.